The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2012Antiparkinsonian Effects of T-type Calcium Channel Inhibitors
Objective/Rationale:
Parkinson’s disease is associated with changes in the electrical activity of nerve cells in the basal ganglia and thalamus, including the emergence of abnormal burst discharges... -
Rapid Response Innovation Awards, 2012A Genetic Strategy to Restore Impaired Noradrenergic Function by Increasing Expression of Noradrenergic Phenotypes in the Locus Coeruleus in Parkinson’s Disease Pre-clinical Models
Objective/Rationale:
Compelling evidence demonstrated that a dysfunction of the locus coeruleus (LC)-
noradrenaline (NE) system in the brain not only contributes to alterations in
cognitive and motor... -
Rapid Response Innovation Awards, 2012Phosphorylated Alpha-synuclein Species as Biomarkers for Diagnosis and Progression in Parkinson’s disease
Objective/Rationale:
Diagnosis of Parkinson’s disease would be facilitated by the discovery of objective biomarkers for identifying it at early stages and differentiating it from other related... -
MJFF Research Grant, 2012The Role of Alpha-synuclein in the Pathogenesis of Parkinson’s Disease in a Pre-clinical Model
Objective/Rationale:
Preliminary data from our laboratory demonstrated that the protein alpha synuclein (a-syn) might play a major role in an inherited autosomal recessive pre-clinical model for... -
MJFF Research Grant, 2012Using External Research Experts to Mine the 23andMe Parkinson’s Dataset
Objective/Rationale:
Currently at 23andMe we have whole-genome genotype data for 5,449 Parkinson’s disease (PD) patients and 110,853 healthy subjects. This is by far the largest cohort of case-control... -
Therapeutics Development Initiative, 2012Targeting System-xc for the Treatment of Parkinson's Disease
Objective/Rationale:
Parkinson’s disease is characterized by the progressive loss of dopamine neurons in brain regions responsible for motor coordination and activity – disturbances of which are...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.